
Opinion|Videos|May 1, 2026
Personalizing Long-Term Treatment of Metastatic Castration-Sensitive Prostate Cancer
Fact checked by: Tracy Ann Politowicz
This episode explores how long-term management of metastatic castration-sensitive prostate cancer is increasingly shaped by personalized treatment planning that balances disease burden, patient fitness, quality of life, and shared decision-making.
Episodes in this series

This episode explores how long-term management of metastatic castration-sensitive prostate cancer is increasingly shaped by personalized treatment planning that balances disease burden, patient fitness, quality of life, and shared decision-making.
Latest CME
Trending on Urology Times
1
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
2
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
3
Trial launches of actinium (225Ac) rhPSMA-10.1 injection in mCRPC
4
FDA greenlights phase 1 study of UGN-501 for NMIBC
5















